International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationCombination of External Beam Radiotherapy (EBRT) With Intratumoral Injection of Dendritic Cells as Neo-Adjuvant Treatment of High-Risk Soft Tissue Sarcoma Patients
Introduction
Intratumoral administration of dendritic cells (DC) is one of the promising methods of induction of therapeutic antitumor immune responses. The main advantage of this approach is that a large variety of tumor-associated antigens present in tumors can be used. In addition, patients do not need to be selected or excluded based on human leukocyte antigen (HLA) type or the expression of specific antigens. However, immunotherapy alone rarely causes curative antitumor effects as the manipulation of tumor microenvironment is necessary to potentiate the effect of DC administration (1). Ionizing radiation presents one such powerful intervention. Radiation can not only kill tumor cells releasing tumor antigens, but can also exert various immunomodulatory effects including induction of the expression of cytokines, chemokines, and release of inflammatory mediators 2, 3, 4. It also increases the permeability of the local vasculature that leads to re-cruitment of circulating leukocytes into surrounding tissues including antigen-presenting cells and effector T cells 5, 6, 7. Thus, the proinflammatory microenvironment within irradiated tumors could provide DCs with maturation-inducing stimuli critical for eliciting effective antigen presentation.
We and others have demonstrated in preclinical studies that local tumor irradiation in combination with intratumoral DC administration but not irradiation alone resulted in potent antitumor immune responses that translated into an antitumor effect 7, 8, 9, 10, 11, 12. These preclinical studies provided a compelling rationale for testing this approach in the clinic. In a Phase I clinical trial of hepatoma, intratumoral administration of DCs in combination with a single high dose of conformal radiation was found to be safe and in some cases resulted in induction of tumor-specific immune responses 13, 14. However, it remains unclear whether conventionally fractionated external beam radiotherapy (EBRT) coupled with DC can cause a robust immune response in a substantial proportion of patients, whether this response correlates with clinical outcome, and whether the treatment affects immune suppressive cells present in cancer patients. In this study, we tested this approach in patients with soft-tissue sarcomas (STS).
Sarcomas are relatively rare neoplasms with approximately 10,000+ new cases occurring in the United States every year. Many studies have shown that the preoperative radiotherapy and surgery is an effective strategy to treat many STS with high-risk features 15, 16, 17, 18. Unfortunately, conventional therapy for large, high-grade tumors is frequently systemically ineffective, which makes this a very deadly problem. Indeed, despite a multidisciplinary, multimodality approach employing radiation therapy and at times systemic chemotherapy, approximately 50% of patients with large, high-grade STS will go on to develop distant metastasis (19). Novel approaches to deal with the systemic potential of this disease are needed.
Section snippets
Patient selection and treatment
Seventeen patients with histologically confirmed large high-grade STS of the extremity/trunk/chest wall were enrolled to the study (Table 1). These patients had clinical stage T2N0M0 with a significant (>50%) risk of progressing to distant metastases. All patients provided written informed consent to an Institutional Review Board of University of South Florida approved protocol. Treatment schema is shown in Fig. S1. Patients were treated with EBRT combined with experimental intratumoral
Clinical response to combination of EBRT with intratumoral DC administration
No significant (≥Grade 2) toxicity was observed during combination EBRT/DC neoadjuvant treatment. Postoperative wound complications were observed in 5/17 patients (29.41%) defined using NCIC criteria (16). Twelve patients (70.6%) had no evidence of the disease for at least one year after the start of the treatment (time of follow-up). Among those 12 patients, 6 are disease-free for more than 2 years and 4 patients for more than 3 years. There were no local recurrences. Pathological evaluation
Discussion
We report the clinical and immunologic results of the first Phase I/II trial in humans combining localized fractionated EBRT with intratumoral administration of DCs in patients afflicted with high-risk STS. Treatment was well tolerated by all patients. The frequency of wound complications (29.1%) was similar to that reported for EBRT alone 16, 28. The proportion of patients remaining disease free 1 year after the treatment (70.6%) was similar to that reported for patients with high-grade, large
Acknowledgments
This manuscript is dedicated in memory of Erin Bryant, our nurse, colleague, and friend.
References (39)
- et al.
Assumptions of the tumor escape hypothesis
Semin Cancer Biol
(2002) - et al.
Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial
Lancet
(2002) - et al.
Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma
Radiother Oncol
(2005) - et al.
Radiation therapy for soft tissue sarcoma
Surg Oncol Clin N Am
(2003) - et al.
Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma
Lancet
(2002) - et al.
Effect of glucocorticoids and gamma radiation on epidermal Langerhans cells
J Invest Dermatol
(1984) Immune modulation by ionizing radiation and its implications for cancer immunotherapy
Curr Pharm Des
(2002)- et al.
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
J Exp Med
(2003) - et al.
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
J Exp Med
(2005) - et al.
Radiation-induced normal tissue injury: Role of adhesion molecules in leukocyte-endothelial cell interactions
Int J Cancer
(1999)
Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication
Cancer Res
Combination of gamma irradiation and dendritic cell administration in treatment of advanced cancer
Intern. J. Cancer
Local administration of dendritic cells inhibits established breast tumor growth: Implication for apoptosis-inducing agents
Cancer Res
Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration
Cancer Res
Combined radiation therapy and dendritic cell vaccine for treating solid tumors with liver micro-metastasis
J Gene Med
Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice
Int J Oncol
Intratumoral dendritic cells and chemoradiation for the treatment of murine squamous cell carcinoma
J Immunother
Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma
J Immunother
Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers
Ann N Y Acad Sci
Cited by (0)
This work was supported by grant from “Gateway for Cancer Research” (to D.I.G.).
S.E.F., C.I., and M.M.B. contributed equally to this work.
Conflict of interest: none